GeoVax Labs

GOVX

Market cap $4.79M

GeoVax Labs, Inc. ( GOVX ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants David Dodd - Chairman, President & CEO Mark Reynolds - CFO & Corporate Secretary John Sharkey - Vice President of Business Development Conference Call Participants Jonathan Aschoff - ROTH Capital Partners, LLC, Research Division Robert LeBoyer - NOBLE Capital Markets, Inc., Research Division Laura Suriel John Vandermosten - Zacks Investment Research, Inc. Presentation Operator Good afternoon, and welcome, everyone, to the GeoVax Third Quarter 2025 Corporate Update Call. My name is Sherry, and I will facilitate today's call.

GeoVax Labs (GOVX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

GeoVax Labs Revenue Doubles in Q2

GeoVax Labs, Inc. (NASDAQ:GOVX ) Q2 2025 Earnings Conference Call July 28, 2025 4:30 PM ET Company Participants David Alan Dodd - Chairman, President & CEO John W. Sharkey - Vice President of Business Development Kelly T.

GeoVax Labs, Inc. (NASDAQ:GOVX ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Max Gadicke - Precision AQ, Investor Relations David Dodd - Chairman, President & Chief Executive Officer Mark Reynolds - Chief Financial Officer Conference Call Participants James Molloy - Alliance Global Partners Robert LeBoyer - Noble Capital Markets Jeffrey Kraws - Crystal Research Associates Operator Good afternoon. And welcome everyone to the GeoVax First Quarter 2025 Corporate Update Call.

GeoVax Labs, Inc. (NASDAQ:GOVX ) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Max Gadicke - Precision AQ, Investor Relations David Dodd - Chairman, President & CEO Mark Reynolds - Chief Financial Officer Kelly McKee - Chief Medical Officer John Sharkey - Vice President, Business Development Conference Call Participants Jonathan Aschoff - ROTH Capital Partners Robert LeBoyer - Noble Capital Markets Laura Suriel - Alliance Global Partners Operator Good afternoon. And welcome everyone to the GeoVax Fourth Quarter Full Year 2024 Corporate Update Call.

Adds to Growing Portfolio of Intellectual Property Assets ATLANTA, Ga., Dec. 09, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for Patent Application No.

Known for their uncommonly pronounced risk/reward profile, penny stocks all too often entice investors with their low prices and potential for significant returns, only to fail to live up to those expectations. The world of penny stocks is also characterized by pump-and-dump and other scams, facilitated by the fact that most penny stock companies do not have an extensive history of financial reporting or an established brand name and presence.

ATLANTA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that its Chairman & CEO, David Dodd, will present at NobleCon20 - the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference taking place December 2-5, 2024 in Boca Raton, FL.

GeoVax Labs, Inc. (GOVX) Q3 2024 Earnings Call Transcript